Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Administration, Oral
  • Blood Transfusion*
  • Erythropoietin / administration & dosage
  • Erythropoietin / therapeutic use*
  • Humans
  • Hydroxamic Acids / administration & dosage
  • Hydroxamic Acids / therapeutic use*
  • Indoles / administration & dosage
  • Indoles / therapeutic use*
  • Myelodysplastic Syndromes / drug therapy*
  • Panobinostat

Substances

  • Hydroxamic Acids
  • Indoles
  • Erythropoietin
  • Panobinostat